Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2012-09-26
- Target Recruit Count
- 3
- Registration Number
- NCT00005612
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
- Conditions
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003133
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 25
- Registration Number
- NCT00003397
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00003394
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 21
- Registration Number
- NCT00002939
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT00004174
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00005649
- Locations
- 🇺🇸
PPD Development, Wilmington, North Carolina, United States
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00006049
- Locations
- 🇺🇸
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT00005849
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Michiana Hematology/Oncology P.C., South Bend, Indiana, United States
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00003899
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.